Literature DB >> 11823691

Severe pulmonary toxicity in a patient treated with gemcitabine.

Manuel F Rosado1, Daniel H Kett, Roland M H Schein, Francisco J Baraona, Kasi S Sridhar.   

Abstract

Gemcitabine is a pyrimidine analog of deoxycytidine with activity against nonhematologic and hematologic malignancies. Its pulmonary toxicity is usually mild and self-limiting. We describe a male patient with lung cancer in whom severe dyspnea and interstitial infiltrates developed after the administration of gemcitabine.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11823691     DOI: 10.1097/00000421-200202000-00005

Source DB:  PubMed          Journal:  Am J Clin Oncol        ISSN: 0277-3732            Impact factor:   2.339


  4 in total

Review 1.  Locally advanced breast cancer: pulmonary toxicity secondary to gemcitabine.

Authors:  Silvia Antolín; Lourdes Calvo; Diana Dopico; María Quindós; Margarita Reboredo; Alberto Carral
Journal:  Clin Transl Oncol       Date:  2010-06       Impact factor: 3.405

2.  Preclinical relevance of dosing time for the therapeutic index of gemcitabine-cisplatin.

Authors:  X M Li; K Tanaka; J Sun; E Filipski; L Kayitalire; C Focan; F Lévi
Journal:  Br J Cancer       Date:  2005-05-09       Impact factor: 7.640

3.  Gemcitabine-Induced Pulmonary Toxicity: A Case Report of Pulmonary Veno-Occlusive Disease.

Authors:  Célia Turco; Marine Jary; Stefano Kim; Mélanie Moltenis; Bruno Degano; Philippe Manzoni; Thierry Nguyen; Bruno Genet; Marie-Blanche Valnet Rabier; Bruno Heyd; Christophe Borg
Journal:  Clin Med Insights Oncol       Date:  2015-09-01

4.  Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report.

Authors:  Francesca Comito; Elisa Grassi; Antonio Poerio; Eva Freier; Lucia Calculli; Maurizio Zompatori; Claudio Ricci; Riccardo Casadei; Mariacristina Di Marco
Journal:  BJR Case Rep       Date:  2018-02-05
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.